Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.2301
-0.0152 (-6.20%)
At close: Apr 1, 2025, 4:00 PM
0.2300
-0.0001 (-0.04%)
After-hours: Apr 1, 2025, 4:51 PM EDT
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$873,460
Market Cap
1.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GNPX News
- 6 days ago - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PRNewsWire
- 7 days ago - Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - PRNewsWire
- 4 weeks ago - Genprex to Participate at BIO Europe Spring 2025 - PRNewsWire
- 5 weeks ago - Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System - PRNewsWire
- 6 weeks ago - Genprex Provides Update on Diabetes Gene Therapy Program - PRNewsWire
- 6 weeks ago - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - PRNewsWire
- 2 months ago - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PRNewsWire
- 3 months ago - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire